Jonathan Israel, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (44.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 61.6% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2020 at $3,068 and has fallen 65.6% since, to $1,055 in 2025.
Across 100 payments — averaging $69.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Angiodynamics, Inc.$478
- Teleflex LLC$305
- Astellas Pharma US Inc$254
- Johnson & Johnson$234
- Neotract Inc.$221
- plus $1K from 21 others
What the payments were for
- Travel & lodging$1,89627%
- Food & beverage$1,99729%
- Education$3,08844%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $4,299 |
| Angiodynamics, Inc. | 2 | $478 |
| Teleflex LLC | 14 | $305 |
| Astellas Pharma US Inc | 11 | $254 |
| Johnson & Johnson | 5 | $234 |
| Neotract Inc. | 3 | $221 |
| AbbVie | 12 | $219 |
| Coloplast | 6 | $154 |
| Astellas Pharma Global Development | 1 | $132 |
| Dendreon Pharmaceuticals LLC | 8 | $112 |
| Pfizer | 5 | $80 |
| Tolmar Pharmaceuticals, Inc. | 3 | $54 |
| Sumitomo Pharma America, Inc. | 2 | $53 |
| Calyxo, Inc. | 1 | $45 |
| Medtronic | 2 | $45 |
| Procept Biorobotics Corporation | 2 | $41 |
| Janssen Scientific Affairs, LLC | 1 | $39 |
| Verity Pharmaceuticals Inc. | 2 | $38 |
| Boston Scientific | 2 | $34 |
| Vertex | 1 | $29 |
| Ambu Inc. | 1 | $24 |
| Blue Earth Diagnostics | 1 | $19 |
| Stryker | 1 | $17 |
| Rochester Medical Corporation | 1 | $16 |
| 180 Medical, Inc. | 1 | $15 |
| Laborie Medical Technologies Corp. | 2 | $12 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,980 in reported general payments places this provider in the 65th percentile of 145 urology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 17 | $13,722 |
| Tamsulosin Hcl | 424 | $7,046 |
| Finasteride | 393 | $5,483 |
| Oxybutynin Chloride ErOxybutynin Chloride | 102 | $1,962 |
| Tolterodine Tartrate ErTolterodine Tartrate | 29 | $1,854 |
| Potassium Citrate ErPotassium Citrate | 15 | $691 |
| Trimethoprim | 13 | $510 |
| Cephalexin | 64 | $483 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 70 | $429 |
| Testosterone Cypionate | 16 | $384 |
| Oxybutynin Chloride | 15 | $364 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 24 | $349 |
| Ciprofloxacin Hcl | 49 | $169 |
| Levofloxacin | 31 | $117 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 22 | $90 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $53 | $13,72217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 145 urology providers in Oklahoma.
Other urology in Tulsa
- Melanie KetchandjiTulsa$111K
- Marc MilstenTulsa$29K
- Scott LitwillerTulsa$27K
- Charles PritchardTulsa$23K
- Sean DoyleTulsa$17K
- Joshua VicenaTulsa$16K
- Curtis PowellTulsa$16K
- Wesley BrookoverTulsa$13K
- Thomas RashidTulsa$12K
- Dae KimTulsa$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.